Abstract
Key Points There is a high burden of extramedullary disease in pediatric patients with relapsed/refractory B-ALL prior to CD19-CAR T cell therapy CD19-CAR T cells can have activity at extramedullary B-ALL sites, but overall response is less robust than for bone marrow disease
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
